Obesity Clinical Trial
Official title:
The Effect of Different Amounts of Coffee on Dietary Intake, Appetite-related Feeling, Appetite Hormones, Glucose Metabolism and Inflammatory Markers of Normal Weight and Overweight/Obese Individuals
Verified date | December 2011 |
Source | Harokopio University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Greece: Ethics Committee |
Study type | Interventional |
The purpose of the study is to investigate whether different doses of caffeinated coffee consumption has acute effects on subjective appetite feelings, energy intake and biochemical markers related to appetite, inflammation and glucose metabolism compared to water consumption in normal weight and overweight/obese participants.
Status | Completed |
Enrollment | 33 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - apparently healthy - habitual coffee drinkers (>= 1cup of coffee/day) Exclusion Criteria: - smokers - restrained eaters (as this was evaluated using the Dutch Eating Behaviour Questionnaire) - those who reported slimming or any other dietary regime - athletes - participants with a known diagnosis of either hypertension, diabetes, impaired glucose tolerance or a fasting blood glucose concentration above 125 mg/dl - subjects on medication for hypertension or on medication known to alter glucose metabolism - subjects who were on medication that may have an impact on appetite and sensory functioning or who reported a metabolic or - endocrine disease, - gastrointestinal disorders, - a history of medical or surgical events that may have affected the study outcomes |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Greece | Metabolic Unit of the Department of Nutrition and Dietetics, Harokopio University | Athens |
Lead Sponsor | Collaborator |
---|---|
Harokopio University |
Greece,
Gavrieli A, Yannakoulia M, Fragopoulou E, Margaritopoulos D, Chamberland JP, Kaisari P, Kavouras SA, Mantzoros CS. Caffeinated coffee does not acutely affect energy intake, appetite, or inflammation but prevents serum cortisol concentrations from falling in healthy men. J Nutr. 2011 Apr 1;141(4):703-7. doi: 10.3945/jn.110.137323. Epub 2011 Feb 23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | energy intake ad libitum | 180 min after breakfast/drink consumption | No | |
Primary | total energy intake | One day | No | |
Primary | appetite feelings | fasting (-15 min) | No | |
Primary | appetite feelings | immediately after breakfast/drink consumption (0 min) | No | |
Primary | appetite feelings | 15 min after breakfast/drink consumption | No | |
Primary | appetite feelings | 30 min after breakfast/drink consumption | No | |
Primary | appetite feelings | 60 min after breakfast/drink consumption | No | |
Primary | appetite feelings | 90 min after breakfast/drink consumption | No | |
Primary | appetite feelings | 120 min after breakfast/drink consumption | No | |
Primary | appetite feelings | 150 min after breakfast/drink consumption | No | |
Primary | appetite feelings | 180 min after breakfast/drink consumption | No | |
Primary | appetite hormones | fasting (-15 min) | No | |
Primary | appetite hormones | immediately after breakfast/drink consumption (0 min) | No | |
Primary | appetite hormones | 15 min after breakfast/drink consumption | No | |
Primary | appetite hormones | 30 min after breakfast/drink consumption | No | |
Primary | appetite hormones | 60 min after breakfast/drink consumption | No | |
Primary | appetite hormones | 90 min after breakfast/drink consumption | No | |
Primary | appetite hormones | 120 min after breakfast/drink consumption | No | |
Primary | appetite hormones | 150 min after breakfast/drink consumption | No | |
Primary | appetite hormones | 180 min after breakfast/drink consumption | No | |
Primary | markers of inflammation | fasting (-15 min) | No | |
Primary | markers of inflammation | immediately after breakfast/drink consumption (0 min) | No | |
Primary | markers of inflammation | 15 min after breakfast/drink consumption | No | |
Primary | markers of inflammation | 30 min after breakfast/drink consumption | No | |
Primary | markers of inflammation | 60 min after breakfast/drink consumption | No | |
Primary | markers of inflammation | 90 min after breakfast/drink consumption | No | |
Primary | markers of inflammation | 120 min after breakfast/drink consumption | No | |
Primary | markers of inflammation | 150 min after breakfast/drink consumption | No | |
Primary | markers of inflammation | 180 min after breakfast/drink consumption | No | |
Primary | markers of glucose metabolism | fasting (-15 min) | No | |
Primary | markers of glucose metabolism | immediately after breakfast/drink consumption (0 min) | No | |
Primary | markers of glucose metabolism | 15 min after breakfast/drink consumption | No | |
Primary | markers of glucose metabolism | 30 min after breakfast/drink consumption | No | |
Primary | markers of glucose metabolism | 60 min after breakfast/drink consumption | No | |
Primary | markers of glucose metabolism | 90 min after breakfast/drink consumption | No | |
Primary | markers of glucose metabolism | 120 min after breakfast/drink consumption | No | |
Primary | markers of glucose metabolism | 150 min after breakfast/drink consumption | No | |
Primary | markers of glucose metabolism | 180 min after breakfast/drink consumption | No | |
Secondary | % carbohydrates ad libitum | 180 min after breakfast/drink consumption | No | |
Secondary | % carbohydrates total day | One day | No | |
Secondary | % protein ad libitum | 180 min after breakfast/drink consumption | No | |
Secondary | % protein total day | One day | No | |
Secondary | % fat | 180 min after breakfast/drink consumption | No | |
Secondary | % fat total day | One day | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |